AU2020289324B2 - Compounds for the treatment of kinase-dependent disorders - Google Patents
Compounds for the treatment of kinase-dependent disordersInfo
- Publication number
- AU2020289324B2 AU2020289324B2 AU2020289324A AU2020289324A AU2020289324B2 AU 2020289324 B2 AU2020289324 B2 AU 2020289324B2 AU 2020289324 A AU2020289324 A AU 2020289324A AU 2020289324 A AU2020289324 A AU 2020289324A AU 2020289324 B2 AU2020289324 B2 AU 2020289324B2
- Authority
- AU
- Australia
- Prior art keywords
- cyclopropane
- dicarboxamide
- oxyphenyl
- fluorophenyl
- quinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856920P | 2019-06-04 | 2019-06-04 | |
| US62/856,920 | 2019-06-04 | ||
| PCT/US2020/035808 WO2020247418A1 (en) | 2019-06-04 | 2020-06-03 | Compounds for the treatment of kinase-dependent disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020289324A1 AU2020289324A1 (en) | 2021-12-16 |
| AU2020289324B2 true AU2020289324B2 (en) | 2026-04-23 |
Family
ID=71842789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020289324A Active AU2020289324B2 (en) | 2019-06-04 | 2020-06-03 | Compounds for the treatment of kinase-dependent disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12503438B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3980404A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7820152B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114040912B (cg-RX-API-DMAC7.html) |
| AR (1) | AR119069A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020289324B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3139156A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA56114A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI850394B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247418A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| CN114573553B (zh) * | 2022-01-27 | 2023-11-10 | 广州六顺生物科技有限公司 | 杂芳环类衍生物及其制备方法和应用 |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
| CN116271008A (zh) * | 2022-12-30 | 2023-06-23 | 广东天普生化医药股份有限公司 | 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104817497A (zh) * | 2015-03-20 | 2015-08-05 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| WO2018049861A1 (zh) * | 2016-09-13 | 2018-03-22 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| WO2019125798A1 (en) * | 2017-12-20 | 2019-06-27 | Angex Pharmaceutical, Inc. | Carbamate and urea compounds as multikinase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US8003662B2 (en) | 2006-01-30 | 2011-08-23 | Array Biopharma, Inc. | Heterobicyclic thiophene compounds and methods of use |
| EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| JP6696908B2 (ja) * | 2014-04-25 | 2020-05-20 | エグゼリクシス, インコーポレイテッド | 肺腺癌の治療方法 |
| CN106279147A (zh) | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
-
2020
- 2020-06-02 AR ARP200101554A patent/AR119069A1/es unknown
- 2020-06-03 WO PCT/US2020/035808 patent/WO2020247418A1/en not_active Ceased
- 2020-06-03 EP EP20747207.7A patent/EP3980404A1/en active Pending
- 2020-06-03 CN CN202080048050.0A patent/CN114040912B/zh active Active
- 2020-06-03 CA CA3139156A patent/CA3139156A1/en active Pending
- 2020-06-03 JP JP2021571941A patent/JP7820152B2/ja active Active
- 2020-06-03 AU AU2020289324A patent/AU2020289324B2/en active Active
- 2020-06-03 MA MA056114A patent/MA56114A/fr unknown
- 2020-06-03 US US17/616,120 patent/US12503438B2/en active Active
- 2020-06-04 TW TW109118785A patent/TWI850394B/zh active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104817497A (zh) * | 2015-03-20 | 2015-08-05 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| WO2018049861A1 (zh) * | 2016-09-13 | 2018-03-22 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| WO2019125798A1 (en) * | 2017-12-20 | 2019-06-27 | Angex Pharmaceutical, Inc. | Carbamate and urea compounds as multikinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202110806A (zh) | 2021-03-16 |
| CA3139156A1 (en) | 2020-12-10 |
| MA56114A (fr) | 2022-04-13 |
| AR119069A1 (es) | 2021-11-24 |
| US12503438B2 (en) | 2025-12-23 |
| AU2020289324A1 (en) | 2021-12-16 |
| JP2022535108A (ja) | 2022-08-04 |
| EP3980404A1 (en) | 2022-04-13 |
| JP7820152B2 (ja) | 2026-02-25 |
| TWI850394B (zh) | 2024-08-01 |
| CN114040912B (zh) | 2024-10-25 |
| US20230043835A1 (en) | 2023-02-09 |
| CN114040912A (zh) | 2022-02-11 |
| WO2020247418A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11542259B2 (en) | Compounds for the treatment of kinase-dependent disorders | |
| US12195475B2 (en) | Compounds for the treatment of kinase-dependent disorders | |
| US12503438B2 (en) | Compounds for the treatment of kinase-dependent disorders | |
| US11673897B2 (en) | Compounds for the treatment of kinase-dependent disorders | |
| TW202519513A (zh) | 激酶抑制劑之結晶形式及鹽形式 | |
| HK40068336A (en) | Compounds for the treatment of kinase-dependent disorders | |
| HK40068336B (en) | Compounds for the treatment of kinase-dependent disorders | |
| BR112020015199B1 (pt) | Composto, composição farmacêutica e uso dos mesmos para tratar distúrbios dependentes de quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 JUL 2026 |